Priovant Therapeutics is a clinicalstage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant is developing oral brepocitinib, a potential firstinclass dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications.